Daniel Gaudet
Université de Montréal
H-index: 84
North America-Canada
Top articles of Daniel Gaudet
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment | European Journal of Preventive Cardiology | Raul D Santos Andrea Ruzza Bei Wang Paul Maruff Adrian Schembri | 2024/2 |
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial | JAMA cardiology | Daniel Gaudet Denes Pall Gerald F Watts Stephen J Nicholls Robert S Rosenson | 2024/4/7 |
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia | Journal of the American Heart Association | Natalia Ryzhaya Lubomira Cermakova Mark Trinder Isabelle Ruel Thais Coutinho | 2021/6/1 |
Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk | New England Journal of Medicine | Brian A Bergmark Nicholas A Marston Thomas A Prohaska Veronica J Alexander André Zimerman | 2024/4/7 |
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study | The Lancet | Kanika Inamdar Dharmayat Antonio J Vallejo-Vaz Christophe AT Stevens Julia M Brandts Alexander RM Lyons | 2024/1/6 |
APOC3 siRNA and ASO therapy for dyslipidemia | Jasmine Chebli Miriam Larouche Daniel Gaudet | 2024/4/1 | |
Comparison of the burden of familial hypercholesterolemia between two cohorts of French Canadians hospitalized 25 years apart for coronary heart disease | Journal of Clinical Lipidology | Alex Lauzière Diane Brisson Gérald Tremblay Sophie Bédard Etienne Khoury | 2024/1/1 |
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial | JAMA | George L Bakris Manish Saxena Anil Gupta Fadi Chalhoub Jongtae Lee | 2024/2/16 |
L’évinacumab: un nouveau médicament dans l’arsenal thérapeutique de l’hypercholestérolémie réfractaire | Archives des Maladies du Coeur et des Vaisseaux-Pratique | M Larouche D Gaudet | 2024/2/16 |
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies | Arteriosclerosis, Thrombosis, and Vascular Biology | Frederick J Raal Robert A Hegele Andrea Ruzza J Antonio G López Ajay K Bhatia | 2024/5 |
Design, Rationale, and Preliminary Results of the Canadian Homozygous Familial Hypercholesterolemia Registry: 2008 to 2022 Update | Canadian Journal of Health Technologies | Leslie Brown Isabelle Ruel Alexis Baass Jean Bergeron Liam R Brunham | 2023/2/10 |
Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial | Journal of clinical lipidology | Joseph L Witztum Daniel Gaudet Marcello Arca Alan Jones Handrean Soran | 2023/5/1 |
ARO-ANG3, an investigational RNAi therapeutic, decreases serum LDL-cholesterol, apolipoprotein B, and angiopoietin-like protein 3 in patients with homozygous familial … | Atherosclerosis | F Raal J Bergeron G Watts D Gaudet D Sullivan | 2023/8/1 |
Clinical trial with the ANGPTL3 monoclonal antibody evinacumab identifies a new rare chylomicronemia causing variant in the LPL gene | Canadian Journal of Diabetes | M Larouche R Pordy P Banerjee D Gaudet | 2023/11/1 |
RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia | NEJM evidence | Daniel Gaudet Peter Clifton David Sullivan John Baker Christian Schwabe | 2023/11/28 |
Comparison of three methods for LDLC calculation for Cardiovascular Disease Risk Categorisation in three distinct patient populations | Canadian Journal of Cardiology | Cathy J Sun Christopher McCudden Diane Brisson Julie Shaw Daniel Gaudet | 2023/5/1 |
Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms | European Heart Journal-Case Reports | Etienne Khoury Alex Lauzière Frederick J Raal John Mancini Daniel Gaudet | 2023/1/1 |
Evolocumab treatment in paediatric patients with homozygous familial hypercholesterolemia: Data from three pooled open-label studies | Atherosclerosis | F Raal A Ruzza JA López A Bhatia J Wu | 2023/8/1 |
Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial … | Journal of Clinical Lipidology | Joseph L Witztum Daniel Gaudet Marcello Arca Alan Jones Handrean Soran | 2023/10/13 |
ARO-APOC3, an investigational RNAi therapeutic, silences APOC3 and reduces atherosclerosis-associated lipoproteins in patients with mixed dyslipidemia: MUIR Study Results | Circulation | Szilard Vasas Masoud Azizad Peter Clifton Daniel Gaudet Ronald Goldenberg | 2023/11/7 |
